Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flucytosine is an antifungal small molecule used primarily to treat serious systemic infections caused by susceptible strains of Candida and Cryptococcus species. It is often administered in combination with amphotericin B for enhanced efficacy, particularly in the treatment of cryptococcal meningitis and other severe fungal infections. Flucytosine acts as an antimetabolite; it enters fungal cells via cytosine permease and is converted intracellularly into 5-fluorouracil (5-FU). The active metabolites disrupt both RNA and DNA synthesis by being incorporated into fungal RNA (as 5-fluorouridinetriphosphate) and inhibiting thymidylate synthase (via 5-fluorodeoxyuridinemonophosphate), leading to impaired protein synthesis and cell death. Resistance can develop rapidly if used as monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flucytosine.